in_alterations,diseases,sources,setting_types,drugs,response,out_alterations
BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,FDA|NCCN,Refractory|Relapse|Treatment Induction,dasatinib,Primary Sensitivity,
ERBB2 Amplification|ERBB2 Overexpression,Breast Carcinoma,FDA|NCCN|MCG|ASCO|BNF,Metastatic,lapatinib,Primary Sensitivity,
ERBB2 Amplification|ERBB2 Overexpression,Breast Carcinoma,FDA|NCCN|ASCO|MCG,Metastatic,ado-trastuzumab emtansine,Primary Sensitivity,
ERBB2 Amplification|ERBB2 Overexpression,Breast Carcinoma,FDA|NCCN|MCG|ASCO|NICE|BNF|SMC,Metastatic|Adjuvant|Neoadjuvant,trastuzumab,Primary Sensitivity,
ERBB2 Amplification|ERBB2 Overexpression,Breast Carcinoma,FDA|NCCN|MCG|ASCO|BNF|NICE,Metastatic|Neoadjuvant,pertuzumab,Primary Sensitivity,
ESR1 Expression|PGR Expression,Breast Carcinoma,FDA|NCCN|MCG|BNF,Metastatic,fulvestrant,Primary Sensitivity,
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,FDA|NICE|BNF|SMC|MCG|NCCN,Relapse|Refractory|Treatment Induction,dasatinib,Primary Sensitivity,
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,FDA|MCG|NICE|BNF|SMC|NCCN,Refractory|Treatment Induction|Relapse,nilotinib,Primary Sensitivity,
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,FDA|NCCN|MCG|NICE|BNF|SMC,Treatment Induction,imatinib,Primary Sensitivity,
ABL1 E255K|ABL1 E255V|ABL1 F317C|ABL1 F317I|ABL1 F317L|ABL1 F317V|ABL1 F359C|ABL1 F359I|ABL1 F359V|ABL1 T315A|ABL1 T315I|ABL1 V299L|ABL1 Y253H|BCR-ABL1 Fusion,Chronic Myeloid Leukemia,NCCN|MCG,Refractory,imatinib,Acquired Resistance,
ABL1 E255K|ABL1 E255V|ABL1 F359C|ABL1 F359I|ABL1 F359V|ABL1 Y253H|BCR-ABL1 Fusion,Chronic Myeloid Leukemia,NCCN|MCG,Refractory|Relapse,dasatinib,Primary Sensitivity,
ABL1 F317L|ABL1 T315I|ABL1 V299L|BCR-ABL1 Fusion,Chronic Myeloid Leukemia,NCCN|MCG,Refractory|Relapse,dasatinib,Acquired Resistance,
ABL1 F317C|ABL1 F317I|ABL1 F317L|ABL1 F317V|ABL1 T315A|ABL1 V299L|BCR-ABL1 Fusion,Chronic Myeloid Leukemia,NCCN|MCG|FDA,Relapse|Refractory,nilotinib,Primary Sensitivity,
ABL1 T315I|ABL1 V299L|BCR-ABL1 Fusion,Chronic Myeloid Leukemia,NCCN,Refractory|Relapse,bosutinib,Primary Resistance,
BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,FDA,Relapse|Refractory,imatinib,Primary Sensitivity,
ABL1 E255K|ABL1 E255V|ABL1 F359C|ABL1 F359I|ABL1 F359V|ABL1 T315I|ABL1 Y253H|BCR-ABL1 Fusion,Chronic Myeloid Leukemia,NCCN|MCG,Refractory|Relapse,nilotinib,Acquired Resistance|Primary Resistance,
ABL1 T315I|BCR-ABL1 Fusion,Chronic Myeloid Leukemia,NCCN|MCG|BNF|SMC,Refractory|Treatment Induction|Relapse,ponatinib,Primary Sensitivity,
ESR1 Expression|PGR Expression,Breast Carcinoma,FDA|NCCN|MCG|ASCO|BNF,Adjuvant|Metastatic,exemestane,Primary Sensitivity,
ERBB2 Amplification|ERBB2 Overexpression,Gastric Carcinoma|Adenocarcinoma of the Gastroesophageal Junction,FDA|NCCN|MCG,Metastatic,trastuzumab,Primary Sensitivity,
KIT Exon 11 Mutation,Gastrointestinal Stromal Tumor,FDA|NCCN|MCG,Metastatic,imatinib,Primary Sensitivity,
BRAF V600E|BRAF V600K,Melanoma,FDA|NCCN|MCG,Metastatic,vemurafenib,Primary Sensitivity,
BRAF V600E|BRAF V600K,Melanoma,FDA|NCCN|MCG|NICE|SMC,Metastatic,dabrafenib,Primary Sensitivity,
BRAF V600E|BRAF V600K,Melanoma,FDA|NCCN|MCG,Metastatic,trametinib,Primary Sensitivity,
EGFR Exon 19 Deletion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I|EGFR T790M,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,afatinib,Acquired Resistance|Primary Resistance,
EGFR Exon 19 Deletion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I|EGFR T790M,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,erlotinib,Acquired Resistance|Primary Resistance,
EGFR Exon 19 Deletion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I|EGFR T790M,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,gefitinib,Acquired Resistance|Primary Resistance,
ALK Fusion,Non-Small Cell Lung Carcinoma,FDA|NCCN|MCG|ASCO|NICE|SMC,Metastatic|First Line of Therapy|Second Line of Therapy,crizotinib,Primary Sensitivity,
BRAF V600E,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,vemurafenib,Primary Sensitivity,
BRAF V600E,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,dabrafenib,Primary Sensitivity,
MET Amplification|MET Exon 14 Skipping,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,crizotinib,Primary Sensitivity,
ROS1 Fusion,Non-Small Cell Lung Carcinoma,FDA|NCCN|MCG|ASCO,Metastatic,crizotinib,Primary Sensitivity,
RET Fusion,Non-Small Cell Lung Carcinoma,NCCN,Metastatic,cabozantinib,Primary Sensitivity,
ERBB2 Exon 20 Insertion,Non-Small Cell Lung Carcinoma,NCCN,Metastatic,afatinib,Primary Sensitivity,
BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,NCCN,Relapse|Refractory,bosutinib,Primary Sensitivity,
EGFR T790M,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,gefitinib,Primary Resistance,
EGFR T790M,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,erlotinib,Primary Resistance,
EGFR T790M,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,afatinib,Primary Resistance,
EGFR Exon 20 Insertion,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,afatinib,Primary Resistance,EGFR A763_Y764insFQEA
EGFR Exon 20 Insertion,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,erlotinib,Primary Resistance,EGFR A763_Y764insFQEA
EGFR Exon 20 Insertion,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,gefitinib,Primary Resistance,EGFR A763_Y764insFQEA
ABL1 E255K|ABL1 E255V|ABL1 F359C|ABL1 F359I|ABL1 F359V|ABL1 Y253H|BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,NCCN,Relapse|Refractory|Maintenance therapy,dasatinib,Primary Sensitivity,
ABL1 F317C|ABL1 F317I|ABL1 F317L|ABL1 F317V|ABL1 T315A|ABL1 V299L|BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,NCCN,Refractory|Relapse,nilotinib,Primary Sensitivity,
ABL1 E255K|ABL1 E255V|ABL1 F317C|ABL1 F317I|ABL1 F317L|ABL1 F317V|ABL1 F359C|ABL1 F359I|ABL1 F359V|ABL1 T315A|ABL1 Y253H|BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,NCCN,Relapse|Refractory,bosutinib,Primary Sensitivity,
ABL1 T315I|BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,FDA|NCCN|BNF|SMC,Refractory|Relapse|Treatment Induction,ponatinib,Primary Sensitivity,
PDGFRA D842V,Gastrointestinal Stromal Tumor,NCCN,Metastatic,dasatinib,Primary Sensitivity,
KIT Exon 11 Mutation|KIT Exon 17 Mutation,Gastrointestinal Stromal Tumor,NCCN,Metastatic,nilotinib,Primary Sensitivity,
KIT Exon 11 Mutation|KIT Exon 9 Mutation,Gastrointestinal Stromal Tumor,NCCN,Metastatic,regorafenib,Primary Sensitivity,
BRAF V600E,Gastrointestinal Stromal Tumor,MCG,Metastatic,imatinib,Primary Resistance,
BRAF V600E,Gastrointestinal Stromal Tumor,MCG,Metastatic,sunitinib,Primary Resistance,
PDGFRA Exon 12 Mutation|PDGFRA Exon 14 Mutation|PDGFRA Exon 18 Mutation,Gastrointestinal Stromal Tumor,NCCN|MCG,Metastatic,imatinib,Primary Sensitivity,PDGFRA D842I|PDGFRA D842V|PDGFRA D842Y
PDGFRA Exon 12 Mutation,Gastrointestinal Stromal Tumor,MCG,Metastatic,sunitinib,Theoretical Primary Sensitivity,
KIT E490K|KIT H697Y|KIT V559A|KIT V560del|KIT W557R,Thymic Carcinoma,MCG,Metastatic,sunitinib,Theoretical Primary Sensitivity,
KIT D820E|KIT E490K|KIT V559A|KIT V560del|KIT W557R,Thymic Carcinoma,MCG,Metastatic,dasatinib,Theoretical Primary Sensitivity,
KIT E490K|KIT V559A|KIT W557R,Thymic Carcinoma,MCG,Metastatic,sorafenib,Theoretical Primary Sensitivity,
KIT E490K|KIT H697Y|KIT V559A|KIT W557R,Thymic Carcinoma,MCG,Metastatic,imatinib,Theoretical Primary Sensitivity,
KIT D820E,Thymic Carcinoma,MCG,Metastatic,imatinib,Theoretical Primary Resistance,
KIT D820E,Thymic Carcinoma,MCG,Metastatic,sunitinib,Theoretical Primary Resistance,
BRAF V600D|BRAF V600G|BRAF V600M|BRAF V600R,Melanoma,MCG,Metastatic,vemurafenib,Theoretical Primary Sensitivity,
SMO D473H,Medulloblastoma,MCG,Metastatic,vismodegib,Primary Resistance,
BRAF Y472C,Non-Small Cell Lung Carcinoma,MCG,Metastatic,dasatinib,Theoretical Primary Sensitivity,
MET Amplification,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,erlotinib,Acquired Resistance|Primary Resistance,
MET Amplification,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,gefitinib,Acquired Resistance|Primary Resistance,
ROS1 Fusion,Non-Small Cell Lung Carcinoma,MCG,Metastatic,erlotinib,Theoretical Primary Resistance,
ROS1 Fusion,Non-Small Cell Lung Carcinoma,MCG,Metastatic,gefitinib,Theoretical Primary Resistance,
ALK Fusion,Inflammatory Myofibroblastic Tumor,MCG,Metastatic,crizotinib,Primary Sensitivity,
,Gastrointestinal Stromal Tumor,MCG,Metastatic,imatinib,Primary Resistance,BRAF Mutation|KIT Mutation|PDGFRA Mutation
ESR1 Expression|PGR Expression,Breast Carcinoma,FDA|NCCN|MCG|ASCO|NICE,Adjuvant|Metastatic|Recurrent,tamoxifen,Primary Sensitivity,
TSC1 E636fs,Bladder Carcinoma,MCG,Metastatic,everolimus,Primary Sensitivity,
PML-RARA Fusion,Acute Myeloid Leukemia,FDA|NCCN|MCG,Treatment Induction|Consolidation Therapy,arsenic trioxide,Primary Sensitivity,
SMO D473H,Basal Cell Carcinoma,MCG,Metastatic,vismodegib,Theoretical Primary Resistance,
RET C634R|RET C634W|RET C634Y|RET Fusion|RET M918T,Thyroid Gland Medullary Carcinoma,MCG,Metastatic,vandetanib,Primary Sensitivity,
PDGFRA D842V,Gastrointestinal Stromal Tumor,NCCN|MCG,Metastatic,imatinib,Primary Resistance,
ABL1 E255K|ABL1 E255V|ABL1 F317C|ABL1 F317I|ABL1 F317L|ABL1 F317V|ABL1 F359C|ABL1 F359I|ABL1 F359V|ABL1 T315A|ABL1 Y253H|BCR-ABL1 Fusion,Chronic Myeloid Leukemia,NCCN,Refractory|Relapse,bosutinib,Primary Sensitivity,
ALK Fusion,Non-Small Cell Lung Carcinoma,FDA|NCCN|MCG|ASCO|NICE|SMC,Metastatic|Second Line of Therapy,ceritinib,Primary Sensitivity,
FLT3 ITD,Acute Myeloid Leukemia,NCCN|MCG,Refractory|Relapse,sorafenib,Primary Sensitivity,
EGFR Exon 19 Deletion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I,Non-Small Cell Lung Carcinoma,FDA|NCCN|MCG|ASCO|NICE|SMC,Metastatic,afatinib,Primary Sensitivity,
EGFR Exon 19 Deletion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I,Non-Small Cell Lung Carcinoma,FDA|NCCN|MCG|ASCO|NICE|SMC,Metastatic,erlotinib,Primary Sensitivity,
EGFR Exon 19 Deletion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I,Non-Small Cell Lung Carcinoma,FDA|NCCN|MCG|ASCO|NICE|BNF|SMC,Metastatic,gefitinib,Primary Sensitivity,
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,erlotinib,Primary Resistance,EGFR A763_Y764insFQEA|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,gefitinib,Primary Resistance,EGFR A763_Y764insFQEA|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,afatinib,Primary Resistance,EGFR A763_Y764insFQEA|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I
EGFR A763_Y764insFQEA|EGFR Exon 19 Insertion,Non-Small Cell Lung Carcinoma,MCG|NICE|SMC,Metastatic,gefitinib,Primary Sensitivity,
EGFR A763_Y764insFQEA|EGFR Exon 19 Insertion,Non-Small Cell Lung Carcinoma,MCG|NICE|SMC,Metastatic,afatinib,Primary Sensitivity,
EGFR A763_Y764insFQEA|EGFR Exon 19 Insertion,Non-Small Cell Lung Carcinoma,MCG|NICE|BNF|SMC,Metastatic,erlotinib,Primary Sensitivity,
PDGFRA D842V,Gastrointestinal Stromal Tumor,MCG,Metastatic,sunitinib,Primary Resistance,
AR Expression,Breast Carcinoma,MCG,Metastatic,bicalutamide,Theoretical Primary Sensitivity,
ESR1 Expression|PGR Expression,Breast Carcinoma,FDA|NCCN|MCG|ASCO|NICE|SMC,Metastatic|Adjuvant,anastrozole,Primary Sensitivity,
,Gastrointestinal Stromal Tumor,MCG,Metastatic,dasatinib,Primary Sensitivity,BRAF Mutation|KIT Mutation|PDGFRA Mutation
KIT Exon 11 Mutation|KIT Exon 9 Mutation,Gastrointestinal Stromal Tumor,NCCN|MCG,Metastatic,sunitinib,Primary Sensitivity,PDGFRA D842V
KIT Exon 11 Mutation|KIT Exon 13 Mutation|KIT Exon 14 Mutation|KIT Exon 17 Mutation|KIT Exon 9 Mutation,Gastrointestinal Stromal Tumor,NCCN,Metastatic,sorafenib,Primary Sensitivity,
EGFR Exon 19 Deletion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Non-Small Cell Lung Carcinoma,NCCN,Metastatic,erlotinib,Primary Resistance,
EGFR Exon 19 Deletion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Non-Small Cell Lung Carcinoma,NCCN,Metastatic,afatinib,Primary Resistance,
EGFR Exon 19 Deletion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Non-Small Cell Lung Carcinoma,NCCN,Metastatic,gefitinib,Primary Resistance,
EGFR Exon 19 Deletion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I|MET Amplification,Non-Small Cell Lung Carcinoma,NCCN,Metastatic,crizotinib|erlotinib,Overcomes acquired resistance,EGFR Exon 20 Insertion|EGFR T790M
EGFR Exon 19 Deletion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I|MET Amplification,Non-Small Cell Lung Carcinoma,NCCN,Metastatic,crizotinib|gefitinib,Overcomes acquired resistance,EGFR Exon 20 Insertion|EGFR T790M
EGFR Exon 19 Deletion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I|MET Amplification,Non-Small Cell Lung Carcinoma,NCCN,Metastatic,afatinib|crizotinib,Overcomes acquired resistance,EGFR Exon 20 Insertion|EGFR T790M
KIT K642E|KIT L576P|KIT V559A|KIT V559D|KIT W557R,Melanoma,MCG,Metastatic,imatinib,Primary Sensitivity,KIT D816H
KIT A829P|KIT D816H|KIT D816V|KIT V654A,Melanoma,MCG,Metastatic,imatinib,Primary Resistance,
,Colorectal Carcinoma,FDA|NCCN|MCG|ASCO|BNF,Metastatic,panitumumab,Primary Sensitivity,BRAF V600E|KRAS A146P|KRAS A146T|KRAS A146V|KRAS A59E|KRAS A59G|KRAS A59P|KRAS A59S|KRAS A59T|KRAS A59V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12F|KRAS G12L|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q22K|KRAS Q61E|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS A59D|NRAS A59G|NRAS A59P|NRAS A59S|NRAS A59T|NRAS A59V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R
KRAS A59E|KRAS A59G|KRAS A59P|KRAS A59S|KRAS A59T|KRAS A59V|KRAS G12F|KRAS G12L|KRAS Q61E|NRAS A146P|NRAS A146T|NRAS A146V|NRAS A59D|NRAS A59G|NRAS A59P|NRAS A59S|NRAS A59T|NRAS A59V|NRAS G12R|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61L|NRAS Q61P,Colorectal Carcinoma,FDA|NCCN|ASCO,Metastatic,panitumumab,Primary Resistance,
MET Amplification,Non-Small Cell Lung Carcinoma,NCCN|MCG,Metastatic,afatinib,Acquired Resistance|Primary Resistance,
KRAS A59E|KRAS A59G|KRAS A59P|KRAS A59S|KRAS A59T|KRAS A59V|KRAS G12F|KRAS G12L|KRAS Q61E|NRAS A146P|NRAS A146T|NRAS A146V|NRAS A59D|NRAS A59G|NRAS A59P|NRAS A59S|NRAS A59T|NRAS A59V|NRAS G12R|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61L|NRAS Q61P,Colorectal Carcinoma,FDA|NCCN|ASCO,Metastatic,cetuximab,Primary Resistance,
ALK Fusion,Non-Small Cell Lung Carcinoma,NCCN|MCG,Relapse,erlotinib,Primary Resistance,
ALK Fusion,Non-Small Cell Lung Carcinoma,NCCN|MCG,Relapse,afatinib,Primary Resistance,
ALK Fusion,Non-Small Cell Lung Carcinoma,NCCN|MCG,Relapse,gefitinib,Primary Resistance,
,Colorectal Carcinoma,FDA|NCCN|MCG|ASCO,Metastatic,cetuximab,Primary Sensitivity,BRAF V600E|KRAS A146P|KRAS A146T|KRAS A146V|KRAS A59E|KRAS A59G|KRAS A59P|KRAS A59S|KRAS A59T|KRAS A59V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12F|KRAS G12L|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q22K|KRAS Q61E|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS A59D|NRAS A59G|NRAS A59P|NRAS A59S|NRAS A59T|NRAS A59V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R
BRAF V600E,Colorectal Carcinoma,MCG,Metastatic,vemurafenib,Theoretical Primary Resistance,
ALK C1156Y|ALK F1174L|ALK Fusion|ALK G1202R|ALK G1269A|ALK L1152R|ALK L1196M|ALK S1206Y|ALK T1151dup,Non-Small Cell Lung Carcinoma,MCG|BNF,Metastatic,crizotinib,Acquired Resistance,
ESR1 Expression|PGR Expression,Breast Carcinoma,FDA|NCCN|MCG|BNF|ASCO|NICE|SMC,Metastatic|Adjuvant,letrozole,Primary Sensitivity,
ESR1 Expression|PGR Expression,Breast Carcinoma,FDA|NCCN|MCG|BNF,Metastatic,toremifene,Primary Sensitivity,
KIT Exon 11 Mutation|KIT Exon 13 Mutation|KIT Exon 17 Mutation|KIT Exon 18 Mutation|KIT Exon 9 Mutation,Melanoma,NCCN|MCG,Metastatic,imatinib,Primary Sensitivity,KIT A829P|KIT D816H|KIT D816V|KIT V654A
ESR1 Expression|PGR Expression,Breast Carcinoma,FDA|NCCN|MCG,Metastatic,everolimus,Primary Sensitivity,
KIT Exon 11 Mutation|KIT Exon 13 Mutation|KIT Exon 14 Mutation|KIT Exon 17 Mutation|KIT Exon 9 Mutation,Gastrointestinal Stromal Tumor,NCCN|MCG,Metastatic,imatinib,Acquired Resistance,
KIT Exon 11 Mutation|KIT Exon 17 Mutation|KIT Exon 18 Mutation|KIT Exon 9 Mutation,Gastrointestinal Stromal Tumor,NCCN|MCG,Metastatic,sunitinib,Acquired Resistance,
EGFR A763_Y764insFQEA|EGFR Exon 19 Insertion|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61R,Non-Small Cell Lung Carcinoma,MCG,Metastatic,gefitinib,Primary Resistance,
EGFR A763_Y764insFQEA|EGFR Exon 19 Insertion|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61R,Non-Small Cell Lung Carcinoma,MCG,Metastatic,erlotinib,Primary Resistance,
EGFR A763_Y764insFQEA|EGFR Exon 19 Insertion|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61R,Non-Small Cell Lung Carcinoma,MCG,Metastatic,afatinib,Primary Resistance,
EGFR A763_Y764insFQEA|EGFR Exon 19 Insertion|EGFR T790M,Non-Small Cell Lung Carcinoma,MCG,Metastatic,afatinib,Acquired Resistance|Primary Resistance,
EGFR A763_Y764insFQEA|EGFR Exon 19 Insertion|EGFR T790M,Non-Small Cell Lung Carcinoma,MCG,Metastatic,gefitinib,Acquired Resistance|Primary Resistance,
EGFR A763_Y764insFQEA|EGFR Exon 19 Insertion|EGFR T790M,Non-Small Cell Lung Carcinoma,MCG,Metastatic,erlotinib,Acquired Resistance|Primary Resistance,
KIT D579del|KIT E554_K558del|KIT E554_V559del|KIT K550N|KIT K558N|KIT N566_D572del|KIT N566_T574del|KIT Q556_W557insL|KIT Q575_L576insPE|KIT V559G|KIT V560A|KIT V560D|KIT V560G|KIT V654A|KIT Y553N,Melanoma,MCG,Metastatic,sunitinib,Primary Sensitivity,
KIT A829P|KIT D816V,Melanoma,MCG,Metastatic,sunitinib,Primary Resistance,
KIT D579del|KIT D820V|KIT D820Y|KIT E554_K558del|KIT E554_V559del|KIT K550N|KIT K558N|KIT N566_D572del|KIT N566_T574del|KIT N822I|KIT N822K|KIT N822Y|KIT Q556_W557insL|KIT Q575_L576insPE|KIT V559A|KIT V559D|KIT V559G|KIT V560A|KIT V560D|KIT V560G|KIT Y553N,Melanoma,MCG,Metastatic,sorafenib,Primary Sensitivity,
KIT D816V,Melanoma,MCG,Metastatic,sorafenib,Primary Resistance,
ABL1 F317L|ABL1 T315I|ABL1 V299L|BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,NCCN,Refractory,dasatinib,Acquired Resistance,
ABL1 E255K|ABL1 E255V|ABL1 F317C|ABL1 F317I|ABL1 F317L|ABL1 F317V|ABL1 F359C|ABL1 F359I|ABL1 F359V|ABL1 T315A|ABL1 T315I|ABL1 V299L|ABL1 Y253H|BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,NCCN,Refractory,imatinib,Acquired Resistance,
ABL1 T315I|BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,NCCN,Relapse|Refractory,nilotinib,Acquired Resistance,
ABL1 T315I|BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,NCCN,Relapse|Refractory,bosutinib,Acquired Resistance,
KIT Exon 11 Mutation|KIT Exon 13 Mutation|KIT Exon 14 Mutation|KIT Exon 9 Mutation,Gastrointestinal Stromal Tumor,NCCN,Metastatic,sunitinib,Theoretical Primary Sensitivity,
KIT Exon 9 Mutation,Gastrointestinal Stromal Tumor,FDA|NCCN|MCG,Metastatic,imatinib,Primary Sensitivity,
KIT Exon 13 Mutation,Gastrointestinal Stromal Tumor,MCG,Metastatic,imatinib,Primary Sensitivity,
KIT Exon 17 Mutation,Gastrointestinal Stromal Tumor,MCG,Metastatic,imatinib,Theoretical Primary Sensitivity,
,Gastrointestinal Stromal Tumor,NCCN,Metastatic,sunitinib,Primary Sensitivity,KIT Mutation|PDGFRA Mutation
ESR1 Expression,Breast Carcinoma,FDA,Metastatic,letrozole|palbociclib,Primary Sensitivity,ERBB2 Amplification|ERBB2 Overexpression
KIT L576P,Thymic Carcinoma,MCG,Metastatic,sunitinib,Primary Sensitivity,
KIT L576P|KIT V560del|KIT Y553N,Thymic Carcinoma,MCG,Metastatic,imatinib,Primary Sensitivity,
KIT D820E|KIT P577_D579del,Thymic Carcinoma,MCG,Metastatic,sorafenib,Primary Sensitivity,
KIT L576P,Thymic Carcinoma,MCG,Metastatic,dasatinib,Primary Sensitivity,
ERBB2 Exon 20 Insertion,Non-Small Cell Lung Carcinoma,NCCN,Metastatic,trastuzumab,Primary Sensitivity,
del(5)(q31q33),Myelodysplastic Syndromes,FDA|NCCN|NICE|BNF|SMC,First Line of Therapy,lenalidomide,Primary Sensitivity,
BRCA1 Frameshift|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Nonsense,Ovarian Cancer,FDA|NCCN,Metastatic|Recurrent,olaparib,Primary Sensitivity,
PML-RARA Fusion,Acute Promyelocytic Leukemia,FDA|NCCN|MCG,Treatment Induction|Consolidation Therapy,arsenic trioxide,Primary Sensitivity,
TP53 Frameshift|TP53 Nonsense|TP53 c.1-c.137 Missense|TP53 c.142-c.212 Missense|TP53 c.217-c.1178 Missense|del(5)(q31q33),Myelodysplastic Syndromes,NCCN|BNF,First Line of Therapy,lenalidomide,Primary Resistance,
KIT Amplification,Melanoma,MCG,Metastatic,imatinib,Primary Resistance,
CD274 High Expression|CD274 Low Expression,Non-Small Cell Lung Carcinoma,NICE|SMC,Second Line of Therapy,pembrolizumab,Primary Sensitivity,
PDGFRA Fusion|PDGFRB Fusion,Myelodysplastic/Myeloproliferative Neoplasm,FDA|NCCN|BNF,First Line of Therapy,imatinib,Primary Sensitivity,BCR-ABL1 Fusion
PDGFRA Fusion|PDGFRB Fusion,Chronic Myelomonocytic Leukemia,FDA|NCCN,First Line of Therapy,imatinib,Primary Sensitivity,BCR-ABL1 Fusion
BRAF V600E|BRAF V600K,Melanoma,FDA|MCG,Metastatic,cobimetinib|vemurafenib,Primary Sensitivity,
EGFR T790M,Non-Small Cell Lung Carcinoma,FDA|NCCN|MCG|NICE|SMC,Metastatic,osimertinib,Primary Sensitivity,
BRAF V600E,Non-Small Cell Lung Carcinoma,NCCN,Metastatic,dabrafenib|trametinib,Primary Sensitivity,
,Myeloproliferative Neoplasm,FDA,Refractory,imatinib,Primary Sensitivity,KIT D816H|KIT D816I|KIT D816V|KIT D816Y
,Acute Lymphoblastic Leukemia,FDA|SMC,Relapse|Refractory,blinatumomab,Primary Sensitivity,BCR-ABL1 Fusion
ALK Fusion,Non-Small Cell Lung Carcinoma,FDA|NCCN,Metastatic,alectinib,Primary Sensitivity,
BIRC3-MALT1 Fusion,Mature B-Cell Lymphoma/Leukemia,NCCN,Refractory,chlorambucil|rituximab,Primary Sensitivity,
BIRC3-MALT1 Fusion,Marginal Zone Lymphoma,NCCN,Refractory,chlorambucil|rituximab,Primary Sensitivity,
CCND1-IGH Fusion,Mature B-Cell Lymphoma/Leukemia,FDA|NCCN,Relapse|Refractory,ibrutinib,Primary Sensitivity,
CCND1-IGH Fusion,Mantle Cell Lymphoma,FDA|NCCN,Relapse|Refractory,ibrutinib,Primary Sensitivity,
BRAF V600E,Hairy Cell Leukemia,NCCN,Relapse|Refractory,vemurafenib,Theoretical Primary Sensitivity,
BRAF V600E,Mature B-Cell Lymphoma/Leukemia,NCCN,Relapse|Refractory,vemurafenib,Theoretical Primary Sensitivity,
BCL2 Fusion|MYC Fusion,Diffuse Large B-Cell Lymphoma,NCCN,Refractory,rituximab,Primary Resistance,
BCL2 Fusion|MYC Fusion,Mature B-Cell Lymphoma/Leukemia,NCCN,Refractory,rituximab,Primary Resistance,
MYD88 L265P,Mature B-Cell Lymphoma/Leukemia,NCCN,Relapse|Refractory,ibrutinib,Primary Sensitivity,CXCR4 Frameshift|CXCR4 Nonsense
MYD88 L265P,Lymphoplasmacytic Lymphoma,NCCN,Relapse|Refractory,ibrutinib,Primary Sensitivity,CXCR4 Frameshift|CXCR4 Nonsense
CXCR4 Frameshift|CXCR4 Nonsense|MYD88 L265P,Mature B-Cell Lymphoma/Leukemia,NCCN,Relapse|Refractory,ibrutinib,Primary Resistance,
CXCR4 Frameshift|CXCR4 Nonsense|MYD88 L265P,Lymphoplasmacytic Lymphoma,NCCN,Relapse|Refractory,ibrutinib,Primary Resistance,
MYD88 S243N,Mature B-Cell Lymphoma/Leukemia,NCCN,Relapse|Refractory,ibrutinib,Theoretical Primary Sensitivity,CXCR4 Frameshift|CXCR4 Nonsense
MYD88 S243N,Lymphoplasmacytic Lymphoma,NCCN,Relapse|Refractory,ibrutinib,Theoretical Primary Sensitivity,CXCR4 Frameshift|CXCR4 Nonsense
ESR1 Expression,Breast Carcinoma,FDA|NCCN,Non-first-line metastatic,fulvestrant|palbociclib,Primary Sensitivity,ERBB2 Amplification|ERBB2 Overexpression
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,NICE|BNF|SMC,Metastatic,vemurafenib,Primary Sensitivity,
ERBB2 Amplification|ERBB2 Overexpression,Gastric Carcinoma|Adenocarcinoma of the Gastroesophageal Junction,NICE|BNF|SMC,Metastatic,capecitabine|cisplatin|trastuzumab,Primary Sensitivity,
ERBB2 Amplification|ERBB2 Overexpression,Gastric Carcinoma|Adenocarcinoma of the Gastroesophageal Junction,NICE|BNF|SMC,Metastatic,cisplatin|fluorouracil|trastuzumab,Primary Sensitivity,
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,NICE|BNF|SMC,Metastatic,dabrafenib,Primary Sensitivity,
BRCA1 Mutation|BRCA2 Mutation,Fallopian Tube Carcinoma|Ovarian Cancer|Peritoneal Carcinoma,BNF|SMC|NICE,Relapse|Maintenance therapy|Fourth line of therapy,olaparib,Primary Sensitivity,
,Colorectal Carcinoma,NICE|BNF|SMC,Metastatic,cetuximab,Primary Sensitivity,KRAS Exon 2 Mutation|KRAS Exon 3 Mutation|KRAS Exon 4 Mutation|NRAS Exon 2 Mutation|NRAS Exon 3 Mutation|NRAS Exon 4 Mutation
,Breast Carcinoma,BNF,Metastatic,everolimus,Primary Sensitivity,
KIT Expression|KIT Overexpression|Mast/stem cell growth factor receptor Kit Expression Positive,Gastrointestinal Stromal Tumor,NICE|BNF|SMC,Adjuvant|Metastatic,imatinib,Primary Sensitivity,
EGFR Expression|EGFR Overexpression|Epidermal growth factor receptor Expression Positive,Colorectal Carcinoma,BNF,Metastatic,irinotecan,Primary Sensitivity,
,Breast Carcinoma,BNF,Neoadjuvant,letrozole,Primary Sensitivity,
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,BNF,Metastatic|Adjuvant|Neoadjuvant|Recurrent,tamoxifen,Primary Sensitivity,
del(17)(p13)|del(5)(q31q33),Myelodysplastic Syndromes,NCCN,First Line of Therapy,lenalidomide,Theoretical Primary Resistance,
ROS1 D2033N|ROS1 Fusion|ROS1 G2032R,Non-Small Cell Lung Carcinoma,MCG,Metastatic,crizotinib,Acquired Resistance,
ROS1 D2033N|ROS1 Fusion,Non-Small Cell Lung Carcinoma,MCG,Metastatic,cabozantinib,Theoretical Primary Sensitivity,
KRAS Q22K,Colorectal Carcinoma,NCCN,Metastatic,cetuximab,Theoretical Primary Resistance,
KRAS Q22K,Colorectal Carcinoma,NCCN,Metastatic,panitumumab,Theoretical Primary Resistance,
CD274 Low Expression,Non-Small Cell Lung Carcinoma,FDA|NCCN|MCG,Metastatic,pembrolizumab,Primary Sensitivity,ALK C1156Y|ALK F1174L|ALK Fusion|ALK G1202R|ALK G1269A|ALK L1152R|ALK L1196M|ALK S1206Y|ALK T1151dup|EGFR A763_Y764insFQEA|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I|EGFR T790M|ROS1 D2033N|ROS1 Fusion|ROS1 G2032R
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12S|NRAS G12V|NRAS Q61K|NRAS Q61R,Colorectal Carcinoma,FDA|NCCN|MCG|ASCO,Metastatic,cetuximab,Primary Resistance,
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12S|NRAS G12V|NRAS Q61K|NRAS Q61R,Colorectal Carcinoma,FDA|NCCN|MCG|ASCO,Metastatic,panitumumab,Primary Resistance,
ESR1 Expression|PGR Expression,Breast Carcinoma,FDA,Metastatic,letrozole|ribociclib,Primary Sensitivity,ERBB2 Amplification|ERBB2 Overexpression
ESR1 Expression|PGR Expression,Breast Carcinoma,FDA,Metastatic,anastrozole|ribociclib,Primary Sensitivity,ERBB2 Amplification|ERBB2 Overexpression
ESR1 Expression|PGR Expression,Breast Carcinoma,FDA,Metastatic,exemestane|ribociclib,Primary Sensitivity,ERBB2 Amplification|ERBB2 Overexpression
CD274 High Expression,Non-Small Cell Lung Carcinoma,FDA|NCCN|MCG,Metastatic,pembrolizumab,Primary Sensitivity,ALK C1156Y|ALK F1174L|ALK Fusion|ALK G1202R|ALK G1269A|ALK L1152R|ALK L1196M|ALK S1206Y|ALK T1151dup|EGFR A763_Y764insFQEA|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I|EGFR T790M|ROS1 D2033N|ROS1 Fusion|ROS1 G2032R
BRAF V600E,Colorectal Carcinoma,NCCN,Metastatic,cetuximab,May Decrease Sensitivity,
BRAF V600E,Colorectal Carcinoma,NCCN,Metastatic,panitumumab,May Decrease Sensitivity,
ALK C1156Y|ALK F1174L|ALK Fusion|ALK G1202R|ALK G1269A|ALK L1152R|ALK L1196M|ALK S1206Y|ALK T1151dup|CD274 High Expression|CD274 Low Expression|EGFR A763_Y764insFQEA|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719S|EGFR L858R|EGFR L861Q|EGFR S768I|EGFR T790M|ROS1 D2033N|ROS1 Fusion|ROS1 G2032R,Non-Small Cell Lung Carcinoma,FDA|NCCN|MCG,Metastatic,pembrolizumab,Primary Sensitivity,
RET Fusion,Non-Small Cell Lung Carcinoma,NCCN,Metastatic,vandetanib,Primary Sensitivity,
ALK Fusion,Non-Small Cell Lung Carcinoma,FDA|MCG,Metastatic,brigatinib,Primary Sensitivity,
FLT3 Codon 835 Missense|FLT3 Codon 836 Missense|FLT3 D835del|FLT3 I836del|FLT3 ITD,Acute Myeloid Leukemia,FDA|MCG,Treatment Induction|Consolidation Therapy,midostaurin,Primary Sensitivity,